Tag: CoreValve
FDA approves Evolut PRO+
The US Food and Drug Administration (FDA) has approved the Evolut PRO+ transcatheter aortic valv...
FDA approves Sapien 3 Ultra, Sapien 3, and CoreValve for low-risk TAVI
On 16 August, the US Food and Drug Administration (FDA) approved Edwards Lifesciences’ Sapien 3 ...
TCT 2018: Longest-term data to date for CoreValve study show excellent valve durability out to five years
New data presented at 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 Septem...
ACC 2018: Five-year data for CoreValve show strong haemodynamic performance
New data from the CoreValve US Pivotal Extreme Risk Study and the real-world NOTION trial (Nordi...
EuroPCR 2017: Study provides “first step” towards showing long-term durability of TAVI devices
New data presented, by Luca Testa (Department of Cardiology, IRCCS Policlinico S. Donato, Milan,...
EuroPCR 2017: Excellent clinical outcomes for Medtronic’s CoreValve and Evolut systems in routine practice
New positive data on the self-expanding Medtronic CoreValve platform from the CoreValve ADVANCE ...
TAVI pacemaker issue is “an engineering problem that will be solved”
The SURTAVI trial indicates that transcatheter aortic valve implantation (TAVI) with CoreValve/...
ACC 2017: FDA approves launch of CoreValve Evolut Pro
The FDA has approved Medtronic’s CoreValve Evolut Pro transcatheter aortic valve implantation (T...
ACC 2017: CoreValve non-inferior to surgery in intermediate-risk patients
Results from the SURTAVI clinical trial, which were presented today at the 2017 scientific sessi...
Japan’s Ministry of Health, Labor and Welfare approves reimbursement for Medtronic’s CoreValve Evolut R system
Medtronic has been granted reimbursement approval from the Japanese Ministry of Health, Labor an...
